• GRCK front-and-center in booming CBD market, which is expected to reach $2.1 billion in annual sales by 2020
• The company provides current and comprehensive information via its CBD Marketplace and CBD TV channel.
• Learning center articles explore various topics, including the benefits of CBD oil for various conditions

Grey Cloak Tech, Inc. (OTCQB: GRCK) is front-and-center in the rapidly-growing medical cannabis market and poised with one-stop information solutions and new age products and services as awareness increases regarding the potential health benefits of cannabinoids.

The timing is right to position GRCK and its wholly-owned subsidiary, Eqova Life Sciences, in a market with CBD products that are projected to grow at an astronomical rate of 700 percent and reach annual sales of $2.1 billion by 2020 (http://dtn.fm/o0BlF). The company is leading strides in this sector by providing comprehensive and current information with the recent launch of a new and cutting-edge internet CBD Marketplace and CBD TV channel.

The online marketplace (www.CBD.co) offers a new-era gateway into all things CBD and hemp oil, including a learning center, e-commerce, and bot/messaging help functionality. The learning center offers information and research articles that explore various topics, such as the differences between CBD and THC and dosage guides. Educational articles offer tantalizing details on the potential benefits of CBD oil for various conditions ranging from pain, migraines, arthritis and anxiety to epilepsy. They also explore safety of its use for children and pets.

Through the marketplace, customers have access to purchase the company’s wide variety of CBD products, including oils, skincare soaps, balms and solutions, vapes and pet products. Transactions are secure, and the marketplace offers engaging and well-organized content, user-friendly navigation and added customer-centric enhanced capabilities with instant bot/messaging help.

In addition, GRCK just launched the company’s brand new YouTube channel, CBD TV (www.CBD.co/tv), as another valuable source for current information. The channel will feature a wide array of content, including educational videos and in-house staff product reviews, as well as interviews with industry leaders and top executives in the CBD and hemp markets. Speaking to the strategy leading to the creation of the new channel, Grey Cloak’s Director of Content and Research, Nicole Gleichmann, stated in a news release, “Frankly, there is no ‘go-to’ source of reliable information on CBD or hemp on the web. Thus, it’s a great honor to bring the CBD Learning Center and CBD TV to the public.”

Gleichmann further indicated that the timing could not be better for the launch. With the sector’s rapid growth and the use of new products and therapies implementing CBD and hemp, now is indeed a good time to poise the company in a market vying to meet increasing demand.

For more information, visit the company’s website at www.GreyCloakTech.com

Let us hear your thoughts: Grey Cloak Tech, Inc. Message Board

• Lexaria’s CEO posts end of 2017 summary
• Multiple transformative developments – IP strengthened, broad patents awarded, finances secured
• Foundation for the future established – multiple opportunities on horizon

If the past is any prologue, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) should have a break out year in 2018. Lexaria’s CEO, Chris Bunka, recently posted ‘LXRP CEO’s End of 2017 Summary’. It was a transformative year with multiple accomplishments that should establish a strong foundation for the future.

Lexaria Bioscience has developed, patented and commercialized a cost-effective lipophilic delivery technology, DehydraTECH™, to enhance the performance of beneficial compounds in ingestible products. Already scientifically proven to enhance absorption of orally ingested cannabinoids, Lexaria’s novel drug delivery platform is believed to be applicable across a wide range of different vitamins, drug types and cannabinoids, dramatically impacting bio-absorption and bioavailability, as well as taste, smell and speed of action.

Lexaria’s DehydraTECH™ technology is a potential game changer for the delivery methodologies of many commonly used active pharmaceutical substances. The technology provides an additional layer of effectiveness designed to harmonize with the intellectual properties of manufacturers, and it can be used with both patented and generic pharmaceutical substances. This breakthrough plays into Lexaria’s long term strategy to partner with leading pharmaceutical, biopharma, nutraceutical, vitamin and food companies to make payload delivery more predictable, safer and more effective.

The first item addressed in the CEO summary was company finances. With a commitment to enhancing shareholder value, Lexaria cleaned up its balance sheet, raised well over $4 million and paid off all its debt. With cash in the bank, the company announced a $1 million budget for R&D using its patented DehydraTECH™ absorption and palatability-enhancing technology to create even more long term value. The company continued multiple absorption tests and formulation experiments, and it continues to pursue a number of intellectual property (IP) enhancement procedures to expand its IP portfolio.

The most significant and transformational developments of 2017 centered on the incredible value created with Lexaria’s intellectual properties. Late in 2016, Lexaria received its first U.S. patent award. Then, in the first half of 2017, the company received its first patent award in Australia. Lexaria announced in November that it had received a broad ranging U.S. patent award for its DehydraTECH™ as a delivery platform for a wide variety of active pharmaceutical ingredients. The U.S. patent includes all cannabinoids including THC, fat soluble vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine. Lexaria is continuing to advance all of its 33 other patent applications pending around the world. The impact of these patents not only creates value and validates Lexaria’s technology; it also opens untold avenues of business opportunity, some of which may be realized over the course of the coming year.

Lexaria has also taken large positions in subsidiary companies that could benefit from the global liberalization of cannabis. Lexaria owns 50 percent of Ambarii Trade Corp., which may offer international opportunities for a class of mouth-melt consumer products delivered with Lexaria’s technology. Lexaria consolidated ownership of PoViva Tea LLC and now own 100 percent. The company also successfully introduced TurboCBD™, a 100 percent-owned brand of hemp oil empowered with DehydraTECH™.

The company’s stock has performed well over the last year and, given all the progress, may outperform in 2018. Lexaria up-listed to the larger, more recognized OTCQX market, and the company filed an S4 prospectus to re-domicile the company from the U.S. to Canada in an effort to exploit opportunities in the Canadian cannabinoid products sector.

As the abundance of good news from last year begins to sink in, it certainly appears that Lexaria is making all the right moves to make 2018 even better.

For more information, visit the company’s website at www.LexariaBioscience.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Offer to expire on February 22, 2018, and represents 4.99 percent of outstanding common shares as of October 31, 2017
• Transaction calls for exchange of 13 shares of IEG Holdings common stock for each share of LendingClub, up to an aggregate of 20.7 million shares
• IEGH sees tender offer as a solid short-term investment for its own shareholders

IEG Holdings Corporation (OTCQB: IEGH) recently announced (http://dtn.fm/zMd0F) that it has begun a tender offer for 4.99 percent of the common shares of LendingClub Corporation (NYSE: LC). The offer, set to expire on February 22, 2018, is for up to an aggregate of 20,701,999 common shares. The transaction calls for the exchange of 13 shares of IEG Holdings common stock for each share of LendingClub.

IEGH believes that the offer is a solid short-term investment for its shareholders. In connection with the offer, IEG Holdings prepared a Letter of Transmittal and submitted a form S-4 with the SEC.

Las Vegas-based IEG Holdings provides $5,000 and $10,000 unsecured consumer loans under the brand name ‘Mr. Amazing Loans’ through its website, www.MrAmazingLoans.com. It is licensed and/or holds certificates of authority to originate direct consumer loans in 20 states. The company provides loans through its online application portal to residents of those states, with all loans originated, processed and serviced out of its centralized Las Vegas head office.

ACF Equity Research, on January 4, 2018, estimated that IEG Holdings revenues in 2018 will reach $2,911,000, compared to $2,135,046 actual in 2016 (http://dtn.fm/KgxK9). The research report noted that ACF also estimates a high 80 percent repeat loan business for the company.

LendingClub (http://dtn.fm/03DsX) offers loans of up to $40,000 for consumers, as well as small business loans of up to $300,000. It is an online marketplace connecting borrowers and investors. It began operations in 2007.

For more information, visit the company’s website at www.InvestmentEvolution.com

Let us hear your thoughts: IEG Holdings Corporation Message Board

• Blockchain technology has the potential to transform supply chain management
• Complex commodity exchanges are traditionally fraught with disputes, driving up costs
• Exclusive blockchain platform for oil and gas industry under development
• Adoption of technology seen as necessary by majority of oil and gas executives

Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is a Canadian-registered, publicly traded company engaged in the development and implementation of proprietary technologies for the environmentally safe extraction of heavy oils from oil sands, oil shale deposits and shallow oil deposits. The company’s proprietary process produces zero greenhouse gas, zero waste and requires no high temperatures. As a forward-thinking pioneer in the energy industry, Petroteq is also participating in a blockchain initiative aimed at solving the global transaction needs of the oil and gas industry.

The company’s entry into the blockchain arena, appropriately named PetroBLOQ, is a collaborative effort with First Bitcoin Capital Corp. (OTC: BITCF) that aims to transform the ongoing problems of disputed oil and gas transactions. PetroBLOQ recently joined the 200-member Enterprise Ethereum Alliance (“EEA”), known as the world’s largest open-source blockchain initiative representing a diverse community of global industry experts (http://dtn.fm/1DLtA). PetroBLOQ is the company’s blockchain technology, the first blockchain-based platform developed exclusively for the supply chain needs of the oil and gas sector.

In a 2016 report issued by Deloitte Consulting and summarized in Rigzone (http://dtn.fm/EKW6u), an online oil and gas industry resource, 55 percent of oil and gas executives surveyed agreed that blockchain technology will be a requirement if companies are to retain a competitive advantage in the future. Another 45 percent acknowledged the disruptive potential that blockchain offers with its ability to encrypt connections and eliminate the role of third parties in transactions. One value of blockchain lies in its ability to fundamentally change the way certain processes are performed, bringing instant transactional verification for product trades.

Blockchains are, by design, built to increase transparency, share efficiencies, securely store and manage data, improve the speed of transactions and, potentially, reduce operating costs. The technology’s ability to create smart contracts offers a distinct advantage to the oil and gas industry, which, historically, has been a hotbed of logistical challenges, as discussed in an article published by the Wall Street Journal (http://dtn.fm/L0LvP). Indeed, experimenting with blockchain to make oil and gas trading more efficient is the subject of discussion around many boardrooms. David Eyton, head of technology for BP, said BP is exploring the implications of using blockchain in the energy sector, noting “there are uses for blockchain that could give us a competitive advantage.”

Petroteq Energy CEO Alex Blyumkin said the blockchain venture makes sense as the oil and gas industry seeks to modernize its resources. With its patented technologies to economically extract heavy oils through an environmentally-friendly, closed loop system, Petroteq is already dramatically lowering the cost per barrel and leaving behind only clean, dry sand. The addition of PetroBLOQ’s blockchain technology will add to the company’s stable of valuable products that underscore its belief in clean, sustainable energy and social responsibility.

For more information, visit the company’s website at www.Petroteq.energy

Let us hear your thoughts: Petroteq Energy Inc. Message Board

• New cannabidiol marketplace offers top-quality products and educational information
• Products offered through the site are carefully vetted for quality and safety
• CBD market estimated to reach $2.1 billion by 2021

Grey Cloak Tech Inc. (OTCQB: GRCK), a growing hemp oil products distributor (through its recently acquired wholly owned subsidiary Eqova Life Sciences), has officially launched CBD.co, a premier online cannabidiol (CBD) marketplace. Grey Cloak Tech and Eqova are working to bring trust and transparency to the burgeoning CBD industry, giving consumers access to the best and latest research, innovations and products.

CBD.co has partnered with leading brands to offer the highest-quality products, and the site also provides customers with clear information and outstanding customer service. Each company offering products through CBD.co has been carefully vetted to ensure that its merchandise has clear and accurate labels, its products adhere to the highest quality and safety standards and its suppliers’ claims have been substantiated.

Cannabidiol and full-spectrum hemp oil have been shown to have positive effects on the mind and body, which makes it extremely unfortunate that so much misinformation exists and so many unscrupulous providers have muddied the marketplace. CBD.co aims to provide a safe and reliable marketplace where CBD and hemp oil users can obtain quality products and reliable information.

Through the website, the best prices and full customer satisfaction are guaranteed. If a patron finds the same product offered elsewhere at a lower cost, CBD.co will immediately refund the difference, plus an additional 10 percent. The site also offers a 100 percent money-back guarantee within 30 days if the consumer is not fully satisfied for any reason.

Additionally, the educational content available on CBD.co is written by well-trained and highly educated health experts, and all of the information has been reviewed by Eqova’s quality and compliance team.

The idea behind CBD.co is to protect consumers and arm them with helpful, educational and transparent information from CBD brands that have met Eqova’s standards and expectations. For those desiring to become educated about CBD and to add it to their supplement routines, CBD.co is a standout, one-stop resource.

For more information, visit CBD.co. To learn more about Grey Cloak Tech and Eqova, visit their respective websites at www.GreyCloakTech.com and www.Eqova.com

Let us hear your thoughts: Grey Cloak Tech, Inc. Message Board

• Substance use disorder (SUD) has reached crisis proportions
• Deal links Quoin’s non-opioid analgesics to Skinvisible’s drug delivery system
• Market for opioids is currently about $6 billion annually

Opioids are killing Americans at an alarming rate. Every day ‘91 Americans die… from an opioid overdose’, according to the Centers for Disease Control and Prevention (CDC). In response to the substance abuse epidemic sweeping the nation, Congress passed the 21st Century Cures Act, which was signed into law by President Obama in December 2016. The legislation allocates over $1 billion to a variety of programs, some of which will attempt to wean patients away from addictive opium derivatives, a push unlikely to cause any degradation in pain management regimens. Non-opiates, in many instances, have proven to be just as effective for pain relief as oxycodone, hydrocodone or codeine, some widely used opioids. In October 2017, President Trump declared a public health emergency to deal with the opioid epidemic. Now that opioid use has reached crisis levels, bringing benign alternatives to market could rescue thousands from the perils of addiction. Skinvisible, Inc. (OTCQB: SKVI) plans to do exactly that. It is teaming up with Quoin Pharmaceuticals, in a proposed merger, to provide pain management products that, unlike opioids, do not provide a cure that is worse than the disease.

The abuse of opioids and other substances continues globally to be a vexing public health issue. The number of people reporting a substance use disorder (SUD) is on the rise, a development attributed to illicit opioids like heroin and opium but also, more alarmingly, to prescription opioid pain relievers (OPRs). The effects have been devastating. In 2015, 33,091 Americans died due to an accidental or unintentional opioid-related overdose. OPR abuse is largely responsible for the increase in SUD fatalities. ‘Deaths from prescription opioids—drugs like oxycodone, hydrocodone, and methadone—have more than quadrupled since 1999’, according to one CDC study (http://dtn.fm/q4SKb). This fourfold increase is in line with the volume of OPRs dispensed: ‘The amount of prescription opioids sold to pharmacies, hospitals, and doctors’ offices nearly quadrupled from 1999 to 2010’, a development that has been blamed on system failure (http://dtn.fm/3rDPp). There is, obviously, a pressing need for less pernicious painkillers. Luckily, there are indications that some non-opiates can be just as effective at reducing pain, as a recent study shows (http://dtn.fm/7JdGR).

Announcing the proposed merger with Quoin Pharmaceuticals Limited, Skinvisible provided an update on how it proposes to address this crisis (http://dtn.fm/P4Dtj). The proposed first lead product, QRX001, is a single use transdermal non-competitive NMDA receptor antagonist intended for the treatment of post-surgical pain. An NMDA receptor antagonist is a type of anesthetic that inhibits the action of the N-Methyl-D-aspartate receptor (NMDAR). Transdermal medicines are those applied to the surface of the skin that then penetrate into the blood stream. QRX001 is expected to provide up to 72 hours of effective analgesia post-surgically, eschewing the use of any opioid.

About half of those addicted were first introduced to opioids to combat pain after surgery. QRX001, when developed, may provide surgeons with a more effective alternative to opioids and to current opioid sparing products such as intravenous NSAIDs. The current market for opioids in the U.S. is estimated at $6 billion annually, and the highly differentiated nature of QRX001 could position it to capture significant market share either as a monotherapy or as part of multi-modal therapy. An application for Fast Track status for QRX001 will be filed.

The proposed merger with Quoin will allow Skinvisible to enter the post-surgical pain management market. The post-merger entity is expected to carry the name Quoin Pharmaceuticals Inc. and be listed on the OTCQB Venture Market.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

• Oil industry services company added millions to its value in 2017 amid expansion effort
• Petrogress, Inc. leadership maintained profitability amid down-revenue period
• Trade partnerships position company to work with major industry players on key shipping routes

News that the oil and gas industry may be entering an extended recovery period following years characterized by decreased prices, a lack of investor confidence and a number of bankruptcies is only adding to the optimism of survivors like Petrogress, Inc. (OTC: PGAS), which capitalized on sound management practices to report a significant rise in profitability during last year’s third quarter and a record adjusted report of earnings despite a slump in the company’s sales volume.

In a news release, PGAS CEO Christos P. Traios stated, “The fact that revenues were down didn’t impact the fact that we still ended up showing a profit… We are stockpiling cash and prepaying expenses and also reflecting the acquisition of our assets in Ghana and Cyprus. We added $3 million-plus to shareholder value, to the book value of the company.”

Petrogress has been building its portfolio, pursuing the acquisition of two Aframax tankers in Dubai that will help the company trade through the Suez Canal as it seeks to further shore up its foothold in North Africa and the Mediterranean. The company is also working with trading partners in Libya and Ghana to advance its refining, production, and other oil and gas-related businesses. Negotiations for an interest in existing facilities at Cyprus’s Port of Limassol give Petrogress critical access to crossroad routes that it needs for providing shipping services and, according to CEO Traios, “exposure to large international oil and gas concerns that are working in the oil fields off the coast of Lebanon and Israel.”

The company’s aim is that the opportunity to forge ties with companies working in the large, long-producing fields in the Middle East will provide it with critical networking resources, as well as profits from the services it provides. A partnership with EDT Offshore, announced last month, expands those opportunities.

In Ghana, a Petrogress African subsidiary is working to secure government contracts, hopeful that company tankers involved in the Nigerian oil trade will be able to operate from a hub port in the Accra area and bid for operations at the currently profitable APG-1 production platform some eight miles offshore. APG-1 will require some platform repairs but provides the potential opportunity to profit not only from the 300 to 500 barrels that can produced daily there, but also from eight other offshore lease blocks, where an estimated 44 billion barrels of oil are believed to be available.

“While that’s clearly a project that would far outpace our current ability to finance, we think the ability to attract major players to participate with them in operations is going to provide some excellent, excellent opportunities for 2018,” Traios said.

The company’s last quarterly report stated that total assets grew during the period from $9.79 million to $14.03 million during the first nine months of 2017.

For more information, visit the company’s website at www.PetrogressInc.com

Let us hear your thoughts: Petrogress, Inc. Message Board

• Company offers game-changing, environmentally-friendly proprietary heavy oil processing and extraction technology
• Company’s proprietary process produces no greenhouse gas or waste, doesn’t require high temperatures and reduces the production cost per barrel
• Partnered with First Bitcoin Capital to develop and operate PetroBLOQ, the world’s first blockchain-based platform exclusively serving supply chain-related needs within the oil and gas industry

Engaged in developing groundbreaking technologies within the energy industry, Petroteq Energy Inc. (TSX.V: PQE) (OTCQX: PQEFF) is focused on creating value by developing and implementing proprietary technologies to extract heavy oils from oil sands, oil shale deposits and shallow oil deposits in an environmentally safe way. Petroteq’s proprietary heavy oil processing and extraction process produces no greenhouse gas and no waste and, also, does not require high temperatures. This technology further significantly reduces the production cost per barrel and can be easily used anywhere on earth as a means of tapping into heavy oil deposits.

As discussed in a recent article (http://dtn.fm/EeE7D), Petroteq recently forged a partnership with First Bitcoin Capital (OTC: BITCF) to bring the benefits of cryptocurrency to the oil and gas industry. The value of the most popular of the cryptocurrencies, bitcoin, began at less than $1,000 per unit at the beginning of 2017 and has skyrocketed throughout the year, breaking the $17,000 mark in December. Bitcoin’s meteoric rise has created a frenzy among investors as they seek opportunities to cash in on its dizzyingly climbing value.

In endeavoring to build advanced oil processing and refining facilities across the globe, Petroteq noted the existence of hindrances relating to supply chain channels within the oil and gas industry—impediments that could be remedied through the use of blockchain technology.

Collaboratively, Petroteq and First Bitcoin Capital are now working to develop and operate PetroBLOQ, which is an enterprise-grade platform based on blockchain that will facilitate the conducting of transactions for oil and gas enterprises around the world.

PetroBLOQ will be the first blockchain-based platform to exclusively serve needs related to the supply chain within the oil and gas industry, addressing issues like cost constraints faced by participants within the industry. It is anticipated that those who use PetroBLOQ will save both time and money and will also benefit from improved transparency, which the blockchain offers, making navigation of the constantly changing global market much easier and giving companies a competitive edge within the oil and gas space.

Particularly suited for addressing issues within the heavily regulated oil and gas industry, blockchain offers exceptional transparency, resistance to change and a secure means of accomplishing tasks beneath the canopy of government protocols and industry specifications. All in all, Petroteq anticipates that the blockchain could completely shake up the way business is conducted within the oil and gas industry.

Quickly bringing PetroBLOQ into important industry circles, Petroteq recently became a member of the Enterprise Ethereum Alliance (http://dtn.fm/Osx9z), as well as the American Petroleum Institute.

For more information, visit the company’s website at www.PetroteqEnergy.com

Let us hear your thoughts: Petroteq Energy Inc. Message Board

• Developing Nature Identical™ peptides derived from Caribbean Blue Scorpion venom to treat, regulate and prevent cancer progression
• Global market for cancer treatments projected to reach $161.3 billion by 2021
• Unique Sol-gel nose-to-brain CBD delivery platform under development to provide clinical relief of various physical disorders
• Global neuropathic pain market estimated at $8.3 billion by 2024
• Proof of concept already demonstrated for dual-gene therapy for type 2 diabetes and obesity
• Global expenditure for diabetes market in 2016 reached $825 billion

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H), headquartered in Vancouver, British Columbia, Canada, is a health sciences company dedicated to researching and developing innovative options for preventive and curative therapies utilizing organic and Nature Identical™ products. The company is strategically staking out select positions in the medically acute areas of diabetes and obesity, pain management, neurological disorders and cancer.

PreveCeutical Medical Inc. had its beginnings in 2009 when Stephen Van Deventer, a seasoned businessman and venture capitalist, and Kimberly Van Deventer, a successful entrepreneur, met and formed a business partnership. The duo created Cornerstone Global Partners, a venture capital and business development company, and became involved in numerous ventures including building companies such as Aurora Cannabis Inc. Taking their interest in the health and wellness market further, the pair began researching how nature and science can work together to benefit health-conscious consumers. Coining and trademarking the word “PreveCeutical” – a combination of the words “preventive” and “pharmaceutical” – was a precursor to the company’s formation and incorporation in October 2015.

The company’s first product was developed in the Dominican Republic and is now marketed and distributed worldwide by PreveCeutical. It is a Caribbean Blue Scorpion venom product sold under the trade name CELLB9®. This product is an oral dilute solution infused with select peptides sourced exclusively from the blue scorpion (Rhopalurus princeps) found only in Caribbean nations. The active potentiated ingredients in CELLB9, which have been used in over 40 countries for over a decade, appear to support health at a deep, cellular level. PreveCeutical’s research team is using proprietary chemistry to generate Nature Identical™ peptides derived from natural compounds found in Caribbean Blue Scorpion venom with the goal of eventually treating, regulating and preventing cancer progression. Peptides are also being used to target an array of disease indications including metabolic disorders, pain management, cancers, cardiovascular and infectious diseases.

PreveCeutical is developing the first nose-to-brain delivery system of cannabinoids (CBDs) with a novel process that prepares insoluble drug-containing nano-micelles and successfully incorporating them into a proprietary sol-gels application, essentially creating a targeted drug delivery vehicle. Intended for use via a nasal spray, this unique formulation rapidly gels upon contact with mucosal tissue, which paves the way for direct nose-to-brain delivery. This novel application eliminates first pass metabolism (stomach, intestines, liver), potentially improving bioavailability and delivering extended time release formulations that may alleviate side effects of higher dosage therapeutics. This CBD-based patented formula is projected to be deployed in selected markets with licensed medical marijuana companies within 18 months.

PreveCeutical is working with four leading Australian research centers to develop a curative therapy for diabetes and obesity. This four-year program involves engineering a novel approach that selectively targets the gene that encodes for the protein PTP-1B, which is implicated and over-expressed in both type-2 diabetes and obesity. PreveCeutical’s gene-silencing technology would effectively “turn off” the genetic signal which leads to the over-production of this key protein molecule, bringing it back down to safe, normalized levels, and prevent the body from storing excessive fat. Diabetes kills one person every six seconds, with more than $800 billion spent globally on the disease.

Another exciting joint venture, established with Sports 1 Marketing, will focus on the therapeutic potential in the peptides and proteins connected to the Caribbean Blue Scorpion venom to potentially treat mild brain injury concussions. Developing a therapeutic product geared towards athletes who suffer from concussions could help alleviate suffering experienced by those who are affected by head trauma.

PreveCeutical Medical’s science and research team is led by Dr. Harendra (Harry) Parekh, Ph.D., who is based at the University of Queensland’s (UQ) Pharmacy Australia Centre of Excellence (PACE), and Dr. Makarand Jawadekar, Ph.D., whose 28 years of R&D experience with Pfizer Inc., is applicable in his role as chief science officer. Research collaborators include Dr. Rakesh Veedu, an emerging expert internationally in the field of molecular medicine, and Professor Grant Ramm, who is currently head of a leading medical research institute located in Brisbane, Australia.

PreveCeutical Medical is partnering with leading industry experts and companies in its quest to be a leader in the preventive health sciences sector. Its Research and Development partnership with UniQuest, the main commercialization company for the University of Queensland, provides PreveCeutical with the rights to all intellectual property arising from projects created under the agreement. PreveCeutical Medical Inc.’s management team brings an extensive portfolio of research experience, product development, deep corporate strategy and capital markets leadership to the company’s core.

For more information, visit the company’s website at www.PreveCeutical.com

Let us hear your thoughts: PreveCeutical Medical Inc. Message Board

• SING at the forefront of $24.5 billion legal cannabis industry and rapidly-growing cryptocurrency market
• The company plans full launch of its proprietary bitcoin-powered credit-debit payment processing platform and end-to-end solutions
• Recent and planned key acquisitions and joint ventures will strengthen SING’s position in booming markets

As a pioneering and innovative company that offers mobile, technology-driven solutions in various markets, including those to be considered high-risk, SinglePoint, Inc. (OTC: SING) is at the forefront of booming sectors including the legal cannabis industry and the cryptocurrency market. With legal marijuana sales projected to reach upward of $24.5 billion by 2021 (http://dtn.fm/ELz0j), coupled with the exponential rise of bitcoin (http://dtn.fm/Bw1aO), the company is poised to offer comprehensive payment and end-to-end solutions that unite the exploding markets.

SinglePoint, through subsidiary SingleSeed, has established a proprietary credit-debit card payment processing platform that utilizes bitcoin rather than conventional bank-held currency. While not specific to any industry, with blockchain technology’s capability to create efficiencies in any sector, SinglePoint’s innovative SingleSeed app is designed to provide an alternative payment solution to the unbanked cannabis market. The platform, soft-launched last November with expected full launch in the first quarter of 2018, was designed to leverage bitcoin, and eventually other cryptocurrencies such as ethereum, to provide cash-alternative options. The solution enables merchants and customers to sell and purchase products utilizing bitcoin-powered debit and credit card-based transactions. In addition, the solution enables merchants to digitally track and automatically update inventories, as well as upload product-related data, such as photos and descriptions.

The fully KYC-AML compliant solution was designed to bypass current federal restrictions and provide cannabis businesses and customers with critically-needed financial transactions, but it is customizable to any company and industry. The payment service provides ease and efficiency of user signup and verification to enable online and prior-to-sale account registration or immediate point-of-sale cryptocurrency transactions.

As addressed in a recent editorial highlighting innovators and opportunities in the skyrocketing market, the potential of solutions by pioneering companies like SING that utilize bitcoin and other cryptocurrencies are clear and will continue to have wide and cross-industry application (http://dtn.fm/jV0Kf). Another article (http://dtn.fm/f8pC9) highlights its industry-wide potential, stating, “Beyond changing the game for U.S. cannabis businesses, this pioneering payment exchange can, and likely will, go even further, enabling businesses of all types — in both high-risk and low-risk markets — to conduct instant card-based transactions that are powered by bitcoin.”

In the meantime, SING is poised to strengthen its position in the rapidly-growing cannabis and cryptocurrency markets. The company strives to continue to solve key issues with the ultimate goal of providing comprehensive, fully-integrated and end-to-end solutions for cannabis companies to manage all daily operations. This is clear with the company’s recent and planned strategic acquisitions and key joint ventures including, but not limited to, its agreements with Global Payout (OTC: GOHE) and AppSwarm (OTC: SWRM). The agreements with GOHE and SWRM will combine strengths to produce further cryptocurrency and payment solution options for the cannabis industry, as well as provide additional value-added solutions that include licensed in-home delivery services.

For more information, visit the company’s website at www.SinglePoint.com

Let us hear your thoughts: SinglePoint, Inc. Message Board